• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
HU Lin, TONG Huan, DING Ru, WANG Zhanbo, YOU Linjun, YANG Jin. Absorption mechanism of silybin in human intestinal Caco-2 cells[J]. Journal of China Pharmaceutical University, 2018, 49(2): 202-208. DOI: 10.11665/j.issn.1000-5048.20180210
Citation: HU Lin, TONG Huan, DING Ru, WANG Zhanbo, YOU Linjun, YANG Jin. Absorption mechanism of silybin in human intestinal Caco-2 cells[J]. Journal of China Pharmaceutical University, 2018, 49(2): 202-208. DOI: 10.11665/j.issn.1000-5048.20180210
shu

Absorption mechanism of silybin in human intestinal Caco-2 cells

More Information
    Graphical Abstract
    • Abstract
  • The aim of this paper was to investigate the absorption mechanism of silybin(SLB)in Caco-2 cells. Concentrations of samples in the study were determined by developing LC/MS/MS method of SLB, propranolol and atenolol in HBSS buffer to calculate apparent permeability coefficient(Papp). When Caco-2 cells were cultured to the 21st day, the TEER were above 350 Ω ·cm2. The Papp of Lucifer yellow was far less than 1 × 10-7 cm/s. As the positive control drugs, The Papp of atenolol and propranolol were similar to those reported in the literature, indicating that the Caco-2 monolayer model was successfully established in this experiment. The Papp(AP-BL) of SLB at 5, 20, and 50 μg/mL were all more than 2×10-6 cm/s, which showed that SLB was a moderately permeable drug. The efflux ratio was greater than 2 indicating the efflux transporter may be involved in the absorption process of SLB. The Papp of silybin-N-meglumine was similar to that of SLB, suggesting that salt formation did not alter the membrane permeability of SLB. In conclusion, the membrane permeability of SLB is good, and its solubility is low. SLB is a BCS class 2 drug. The release of SLB in the gastrointestinal tract is an important factor in its absorption process.
    • FullText(HTML)
    • References (16)
  • [1]
    Bijak, M. Silybin, a major bioactive component of milk thistle(silybum marianum l.gaernt.)-chemitry,bioavailability,and metabolism [J].Molecules,2017,22(11):1942.
    [2]
    Chu Y,Li W,Han JP,et al.Study on pharmacokinetics of silibinin capsule in Chinese healthy volunteers [J].Chin Pharmacol Bull,2009,25(12):1669-1672.
    [3]
    Javed S,Kohli K,Ali M.Reassessing bioavailability of silymarin [J].Altern Med Rev,2011,16(3):239-249.
    [4]
    Xu D,Ni R,Sun W,et al.In vivo absorption comparison of nanotechnology based silybin A tablets with its water-soluble derivative [J].Drug Dev Ind Pharm,2015,41(4):552-559.
    [5]
    Yang QX,Ma FJ,Zhang LL,et al.Absorption characteristics of silybin-phospholipid complex by rat intestine [J].Acad J Second Military Med Univ,2009,30(11):1288-1291.
    [6]
    Luan LB,Zhan N.The absorption characteristics of silybinin small intestine of rat [J].Acta Pharm Sin,2006,41(2):138-141.
    [7]
    Wang Y,Zhang D,Liu Z,et al.In vitro and in vivo evaluation of silybin A nanosuspensions for oral and intravenous delivery [J].Nanotechnology,2010,21(15):155-168.
    [8]
    Smetanová L,Štětinová V,Svoboda Z,et al.Caco-2 cells,biopharmacrutics classification system(BCS)and biowaiver [J].Acta Medica(Hradec Králové),2011,54(1):3-8.
    [9]
    Wuyts B,Riethorst D,Brouwers J,et al.Evaluation of fasted state human intestinal fluid as apical solvent system in the Caco-2 absorption model and comparison with FaSSIF[J].Eur J Pharm Sci,2015(67):126-135.
    [10]
    Waterbeemd H,Lennernäs H,Artursson P.Drug Bioavailability(药物生物利用度)[M].Beijing:Beijing Chemical Industry Press,2007:82.
    [11]
    FDA.Guidance for industry bioanalytical method validation[S].2013:1-11.
    [12]
    Srinivasan B,Kolli AR,Esch MB,et al.TEER measurement techniques for in vitro barrier model systems [J].Jala J Lab Autom,2015,20(2):107-126.
    [13]
    Artursson P.Epithelial transport of drugs in cell culture I:a model for studying the passive diffusion of drugs over intestinal absorbtive(Caco-2)cells[J].J Pharm Sci-US,1990,79(6):476-482.
    [14]
    Artursson P,Palm K,Luthman K.Caco-2 monolayers in experimental and theoretical predictions of drug transport [J].Adv Drug Deliver Rev,2001,46(1/2/3):27-43.
    [15]
    Tan ZR,Zhou YX,Liu J,et al.The influence of ABCB1 polymorphism C3435T on the pharmacokinetics of silybinin [J].J Clin Pharm Ther,2015,40(6):685-688.
    [16]
    Krishna R,Yu L.Biopharmaceutics Applications in Drug Development(生物药剂学在药物研发中的应用)[M].Beijing:Peking University Medical Press,2012:36.
    • Related Articles

  • Related Articles

    [1]XU Linhao, LIU Xinze, LIU Wei, XIANG Ping, HANG Taijun, YANG Shuo, YAN Hui. Application of zebrafish model in the metabolism of new psychoactive substances[J]. Journal of China Pharmaceutical University, 2022, 53(5): 606-612. DOI: 10.11665/j.issn.1000-5048.20220511
    [2]CHENG Liyuan, LIU Wei, GUO Xiaoyan, GE Xiaoai, WANG Dingding, WANG Tao. Effects and mechanism of zidovudine on glucolipid metabolic balance in mice[J]. Journal of China Pharmaceutical University, 2022, 53(3): 340-347. DOI: 10.11665/j.issn.1000-5048.20220312
    [3]WANG Jingqi, WANG Ye, ZHANG Yi, LIANG Juncheng, DENG Yanping, HANG Taijun, SONG Min. Metabolomic study on clinical staging of methamphetamine detoxification by LC-QTOF-MS[J]. Journal of China Pharmaceutical University, 2022, 53(3): 314-322. DOI: 10.11665/j.issn.1000-5048.20220309
    [4]HE Mingzhe, PENG Ying, WANG Guangji, A Jiye, ZHENG Yiwen, SUN Jianguo. Mechanism of sodium salicylate-induced damage to HEI-OC1 cells based on metabonomics[J]. Journal of China Pharmaceutical University, 2021, 52(5): 566-572. DOI: 10.11665/j.issn.1000-5048.20210508
    [5]WU Yubing, YIN Lifang, QIN Chao. Clinical application and detection of matrix metalloproteinases in diagnosis[J]. Journal of China Pharmaceutical University, 2020, 51(5): 614-621. DOI: 10.11665/j.issn.1000-5048.20200514
    [6]TAO Yingjun, WU Jie, LIU Chang. Application of proteomics in diabetes and its complications[J]. Journal of China Pharmaceutical University, 2020, 51(3): 368-373. DOI: 10.11665/j.issn.1000-5048.20200315
    [7]YIN Kunpeng, ZHENG Hao, XIE Binxin, LI Ping, ZHANG Lei, FAN Yong, ZHU Wei, QI Lianwen. Clinical metabolomics in diagnosis and therapy of coronary artery disease[J]. Journal of China Pharmaceutical University, 2017, 48(6): 629-634. DOI: 10.11665/j.issn.1000-5048.20170601
    [8]ZHANG Xue, WANG Yuhao, ZHENG Yunsi, HE Hua, LIU Xiaoquan. Evaluation of the protective effect of salvianolic acid A on ischemic heart failure by a multi-target pharmacokinetic-pharmacodynamic model[J]. Journal of China Pharmaceutical University, 2016, 47(5): 587-594. DOI: 10.11665/j.issn.1000-5048.20160514
    [9]LI Chen, YUAN Linhua, MA Xueqin, LIU Xiaoquan, XI Tao. Variation of cardiovascular risk biomarkers in type 2 diabetes mellitus[J]. Journal of China Pharmaceutical University, 2013, 44(3): 257-262. DOI: 10.11665/j.issn.1000-5048.20130314
    [10]HUANG Yin, XU Fengguo, ZHANG Wei, ONG Choonnam, ZHANG Zunjian. Progress for pharmacometabolomics and its applications[J]. Journal of China Pharmaceutical University, 2013, 44(2): 105-112. DOI: 10.11665/j.issn.1000-5048.20130202

Catalog

    Get Citation
    PDF
    XML
    Article views (821) PDF downloads (1897) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：300509

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return